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 Key Points 
 1. Cavernous haemangiomata are the most common be-
nign solid tumour of the liver.
2. Giant haemangiomata are defined as those measuring 
 6 5 cm in diameter.
3. The natural history of liver haemangiomata is gener-
ally uncomplicated.
4. Liver function tests are usually normal.
5. The successful management of giant haemangiomata 
depends on establishing the diagnosis, determining 
the requirement for surgical intervention and, where 
necessary, defining the optimal type of surgery.
6. Patients must be counselled that surgery may not al-
leviate their symptoms.
7. Surgery should only be considered for patients with 
complicated or symptomatic lesions, or where the di-
agnosis remains uncertain despite appropriate spe-
cialist investigation.
Introduction
 Liver haemangiomata are a common incidental find-
ing, reflecting a high prevalence within the population. 
With increasing application and resolution of abdominal 
imaging modalities, haemangiomata are detected more 
frequently. Originating from the mesodermal layer, these 
lesions represent a congenital, non-neoplastic hamartoma-
tous proliferation of vascular endothelial cells  [1] . Current 
evidence indicates that haemangiomata have no malignant 
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 Abstract 
 Background: Haemangiomata are the most frequent be-
nign solid liver lesion. The management of giant ( 6 5 cm) 
haemangiomata of the liver remains controversial.  Methods: 
A search of relevant peer-reviewed literature was conducted 
using PubMed and original articles were reviewed.  Results 
and Conclusions: The vast majority of giant haemangioma-
ta remain asymptomatic and have a benign and uncompli-
cated natural history. Decisions regarding the optimal man-
agement of giant haemangiomata depend on a high level
of confidence in diagnostic imaging. Diagnostic biopsy to 
differentiate giant haemangiomata from malignant lesions 
should be discouraged. Despite limitations and alternative 
modalities, surgery remains the only consistently effective 
curative treatment for giant haemangiomata. Surgery is not 
generally justified to prevent complications in asymptom-
atic patients. Principal indications for the surgical manage-
ment of giant haemangiomata include established compli-
cations, incapacitating symptoms and uncertainty of diag-
nosis. Patients should only be selected for surgery based on 
a careful assessment of risks and benefits of intervention. 
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potential. Macroscopically, haemangiomata are well-cir-
cumscribed, hypervascular and compressible lesions with 
a clear sheath of compressed liver parenchyma between 
haemangiomatous tissue and normal liver  [2] . Microscop-
ically, haemangiomata typically consist of ectatic blood-
filled spaces, lined with vascular endothelium and sepa-
rated by fibrous septa with a variable sclerotic component.
 Approximately 80% of haemangiomata are of the cav-
ernous type. Unlike the less common capillary type, 
which are generally smaller in size, more frequently mul-
tiple and do not generally cause symptoms, cavernous 
haemangiomata can grow to reach large sizes and may 
become symptomatic. Giant haemangiomata are defined 
as those measuring  6 5 cm in diameter  [3] .
 The first resection of a liver haemangioma was report-
ed by Hermann Pfannenstiel in 1898. Today, surgery is 
the most effective therapeutic modality for the definitive 
treatment of liver haemangiomata  [4] . However, the opti-
mal approach for the management of patients with giant 
haemangiomata remains controversial.
 Cavernous Haemangioma: Presentation and
Natural History 
 Cavernous haemangiomata are the most common be-
nign solid tumour of the liver  [5] and have been reported 
in up to 7.3% of autopsy studies  [6] . These lesions are more 
usually found in women (female:male ratio = 5: 1), with a 
mean age at diagnosis of 50 years, most lesions being de-
tected between the 3rd and 5th decades. Prevalence is 
greatest in women with higher parity  [7, 8] . Although 
there is no proven association with oral contraceptive use, 
this relationship remains controversial. Cavernous hae-
mangiomata occur more frequently within the right liver 
and multiple lesions occur in 10% of cases  [6] . Similar hae-
mangiomatous lesions may occur in other organs  [9] .
 The majority of evidence indicates that the natural his-
tory of liver haemangiomata is uncomplicated  [10–13] and 
most lesions are asymptomatic. Symptoms associated with 
haemangiomata should be interpreted cautiously. In a se-
ries of 87 patients with liver haemangioma, Farges et al. 
 [10] reported that 54% of these patients had other identifi-
able causes for their abdominal symptoms. While lesions 
 ! 10 cm in diameter seldom cause symptoms, patients with 
larger lesions may present with abdominal pain, due to 
stretching of Glisson’s capsule, compression of local struc-
tures, intralesional thrombosis and infarction or, less 
commonly, haemorrhage. The risk of clinically relevant 
haemorrhage appears to be less than 1%  [14] . Haemangio-
mata tend to remain stable in size. Weimann et al.  [15] re-
ported size increases in 11 (10.6%) of 104 patients with liv-
er haemangiomata. Jaundice is unusual and, despite reach-
ing large dimensions, spontaneous rupture of a giant 
haemangioma is exceptional. While fewer than 50 cases of 
spontaneous rupture have been reported  [10] , the mortal-
ity rate can be appreciable, up to 60% in one series  [16] . 
Traumatic rupture is a recognised but rare complication 
with a handful of cases described in the literature  [17] .
 Liver function tests (LFT) are generally normal in the 
presence of giant haemangioma, although LFT abnor-
malities have been reported as a consequence of biliary 
compression by the mass  [18] . Patients with a giant 
 haemangioma may exhibit inflammatory features, and 
Bornman et al.  [19] described a clinical triad in 4 patients, 
consisting of signs suggestive of an acute inflammatory 
process within the liver, normal white cell count and nor-
mal LFT. Haematological markers of inflammation, e.g. 
raised erythrocyte sedimentation rate, thrombocytosis 
and hyperfibrinogenaemia, may be detected in associa-
tion with giant haemangioma and can be reversed by re-
section  [20] . However, in a further small group of patients 
with giant haemangioma exhibiting inflammatory fea-
tures, none displayed a leucocytosis  [18] . Clinical features 
of polymyalgia rheumatica have also been described in
association with a giant cavernous haemangioma. These 
features also resolved following resection of the lesion  [21] .
 Kasabach-Merritt syndrome  [22] is characterised by 
thrombocytopenia and consumptive coagulopathy in as-
sociation with large haemangiomata ( fig.  1 ), and may 
prompt intervention. Platelet trapping in the haemangi-
oma is thought to result in activation of platelets and the 
clotting cascade, resulting in a consumptive coagulopa-
thy  [22] . The mortality rate of Kasabach-Merritt syn-
drome approaches 30%  [23] .
 Reported Experience 
 In a series of 163 hepatic haemangiomata, reported by 
Farges et al.  [10] , with a mean follow-up of 92 months,
only 9 haemangiomata increased in size and 7 decreased. 
Complications included 2 cases of Kasabach-Merritt syn-
drome, 1 intrahepatic bleed, and 2 cases of Budd-Chiari 
syndrome. 16 patients underwent intervention including 
8 resections, 5 arterial embolisations, 2 transjugular in-
trahepatic portosystemic shunts, 1 right hepatic artery li-
gation, and 1 liver transplantation. Liver transplantation 
has been used by a number of groups for unresectable dis-
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have also reported extracorporeal resection for ‘unresect-
able’ giant haemangiomata  [25] . Non-operative adjunc-
tive measures such as transarterial bland embolisation or 
chemoembolisation have been reported as a ‘bridge to 
surgery’  [26] , as well as a unimodality treatment.
 In a series of 115 patients, recognised as being selected 
surgical referrals, Yoon et al.  [27] reported 6 episodes of 
thrombosis and 3 cases of infarctions or necrosis, but no 
cases of rupture. The authors concluded that complica-
tions were uncommon and that indications for resection 
should include severe symptoms, inability to exclude ma-
lignancy and complications. These authors advocated 
enucleation, first described by Alper et al.  [28] in 1988, 
with good long-term outcomes  [29] .
 Lerner et al.  [4] reported outcomes from a case series 
of 52 resections for giant cavernous haemangioma. This 
group has moved towards a policy of enucleation rather 
than resection over time. The perceived benefits of enu-
cleation over resection include reduced intraoperative 
blood loss, reduced bile leak rates  [30] as well as maximis-
ing preservation of functional hepatic parenchyma.
 In a series from the Memorial Sloan-Kettering Center, 
35% of resections were performed in asymptomatic pa-
tients. Haemangiomata  1 10 cm were overrepresented in 
the resected group (58%), the median size in this group 
being 11 versus 4 cm in the unresected group. In this se-
ries, enucleation was performed in 14% of cases where 
malignancy was suspected. Enucleation of potentially 
malignant lesions is difficult to justify and data regarding 
the long-term outcome of this approach are not available.
 Management 
 The successful management of giant haemangiomata 
depends on: (1) confirming the diagnosis; (2) determin-
ing whether the lesion requires surgical treatment; (3) de-
termining the optimal type of surgery, and (4) avoiding 
unnecessary surgical intervention. A detailed history 
should be obtained, addressing relevant risk factors. 
Symptoms unrelated to an incidentally detected haeman-
gioma should be clarified and alternative cases, e.g. cho-
lelithiasis, liver disease, excluded. Liver biochemistry is 
usually normal, although abnormalities may indicate 
haemorrhage, infarction, neoplasia or be associated with 
a non-haemangiomatous aetiology.
 Management: The Case for Observation 
 In the face of a large body of evidence indicating a be-
nign and uncomplicated natural history for the majority 
of haemangiomata, including giant haemangiomata, a 
policy of non-operative management will be the optimal 
approach for the majority of patients. While morbidity 
and mortality rates associated with liver resection and 
enucleation in specialist centres are low, adverse events 
do occur. The risk of potential complication must be care-
fully weighed against operative risk. Surgery should 
therefore be reserved for cases of absolute necessity.
 The decision to manage giant haemangiomata expec-
tantly depends largely on the certainty of diagnosis, 
which in turn is reliant on the quality of non-invasive 
imaging and its interpretation. Transabdominal ultra-
sound is diagnostic in approximately two thirds of cases 
 [31] . However, axial imaging will usually also be under-
taken. Haemangiomata tend to be hypodense on non-
contrast computerised tomography and show peripheral 
followed by central enhancement. Isoenhancement with 
the arteries is typical. Delayed scans show persisting con-
trast enhancement and features such as corkscrewing 
and ‘cotton wool’ appearance reflect the abnormal ves-
sels within the lesion. Globular enhancement, isodense 
with the aorta, has been shown to be 67% sensitive and 
100% specific in differentiating haemangiomata from 
metastases  [32] .
 Magnetic resonance imaging (MRI) may be of value in 
establishing the diagnosis. Typical features include high 
signal intensity on T 2 -weighted series and discontinuous 
nodular peripheral enhancement ( fig. 2 ). In some cases, 
MRI features can be correlated with histological ones, e.g. 
presence of hypocellular myxoid tissue  [33] .
 Applying a combination of axial imaging modalities 
will generally allow the diagnosis of haemangioma
 Fig. 1. Giant haemangioma of the right lobe which was associated 




















   
   
   
   
   
   
   
   
   
























to be made with an adequate degree of certainty to jus-
tify a plan of expectant management. The static nature 
of giant haemangiomata means that once the diagnosis 
is established, further follow-up may be unnecessary 
 [34] .
 Management: The Case for Operative Management 
 Established Complications. In the minority of cases 
that present as a surgical emergency due to haemorrhage, 
rupture, thrombosis and infarction, surgical manage-
ment may be the only appropriate course of action. There 
is also a role for the elective surgical management of giant 
haemangiomata, albeit in a highly selected group of pa-
tients. As demonstrated by the data presented above, an 
operative approach with the objective of preventing fu-
ture complications of giant haemangiomata is less easy to 
justify.
 Diagnostic Uncertainty. Despite improvements in non-
invasive imaging technology, cases of diagnostic uncer-
tainty continue to pose a challenge. In situations where it 
is not possible to exclude malignancy, surgical interven-
tion by formal liver resection may be indicated. In almost 
all situations, the use of percutaneous liver biopsy for the 
differentiation of giant haemangiomata from malignant 
liver lesions cannot be justified. The risks of haemorrhage 
as a result of biopsying a giant haemangioma are appre-
ciable and, together with the risks of needle track seeding 
and intra-abdominal dissemination of a potentially cur-
able malignancy, mean that biopsy in this setting must be 
avoided.
 Incapacitating Symptoms. Having taken all possible 
steps to ensure that symptoms are attributable to the 
 haemangioma, surgical resection may be justified on 
grounds of intractable symptoms. Patients with clearly 
defined abdominal compressive symptoms may be more 
likely to derive benefit from surgery than patients with 
non-specific abdominal discomfort, although this is not 
backed up by a meaningful body of evidence. Manage-
ment of this group of patients is, by necessity, highly in-
dividualised. Despite apparently satisfactory surgical 
management, symptoms persist in approximately 25% of 
patients following resection of seemingly symptomatic 
haemangiomata.
 Conclusions 
 Decision-making with regard to the optimal manage-
ment of giant haemangiomata depends on a high level of 
confidence in diagnostic imaging. Diagnostic biopsy to 
differentiate giant haemangiomata from malignant le-
sions should in general be discouraged. The risks of po-
tential complications and the severity of symptoms need 
to be carefully weighed against surgical risk. Patients 
must be counselled that surgery may not alleviate their 
symptoms and an individualised approach is essential. 
Despite limitations and alternative modalities, surgery 
remains the only consistently effective curative treatment 
for giant haemangiomata and should be considered for 
patients with complicated or symptomatic lesions, where 
operative risk is acceptable, or where the diagnosis re-
mains uncertain despite appropriate specialist investiga-
tion. The choice of enucleation versus formal resection 
depends upon factors including the certainty of diagnosis 
and anatomical considerations such as the location and 
extent of the lesion. Formal resection may be preferable 
for potentially malignant lesions, and for lesions that to-
tally replace an anatomical section of the liver. However, 
enucleation offers the benefit of potentially lower opera-
tive morbidity.
 The advent of minimally invasive resectional liver sur-
gery offers the possibility for the further reduction of 
perioperative morbidity and mortality. While this devel-
opment should not substantially lower the threshold for 
selecting haemangioma patients for surgery, if individual 
surgeons can demonstrate more favourable outcomes for 
those treated laparoscopically than by open surgery, this 
approach may alter the balance of risk and benefit in fa-
vour of surgical management of giant haemangiomata in 
a small proportion of symptomatic patients. 
 Fig. 2. T 2 -weighted MRI of giant haemangioma replacing much 
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